Xanthohumol, a prenylated chalcone derived from hops, inhibits proliferation, migration and interleukin-8 expression of hepatocellular carcinoma cells

International Journal of Oncology

Volumn 36, Issue 2, 2010, Pages 435-441

  Dorn, Christoph ^a   Weiss, Thomas S ^a   Heilmann, Jörg ^a   Hellerbrand, Claus ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

Apoptosis; Chalcone; Hepatocellular carcinoma; Migration; Proliferation; Xanthohumol

Indexed keywords

CASPASE 3; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 8; TUMOR NECROSIS FACTOR; XANTHOHUMOL;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CARCINOMA CELL; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CELL; LIVER CELL CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; FLAVONOIDS; HUMANS; HUMULUS; INTERLEUKIN-8; LIVER NEOPLASMS; PROPIOPHENONES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 75449084734     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo-00000517     Document Type: Article

References (46)

1. Miranda CL, Stevens JF, Helmrich A, Henderson MC, Rodriguez RJ, Yang YH, Deinzer ML, Barnes DW and Buhler DR: Antiproliferative and cytotoxic effects of prenylated flavonoids from hops (Humulus lupulus) in human cancer cell lines. Food Chem Toxicol 37: 271-285, 1999.
2. Pan L, Becker H and Gerhauser C: Xanthohumol induces apoptosis in cultured 40-16 human colon cancer cells by activation of the death receptor- and mitochondrial pathway. Mol Nutr Food Res 49: 837-843, 2005.
3. Vanhoecke B, Derycke L, Van MV, Depypere H, De KD and Bracke M: Antiinvasive effect of xanthohumol, a prenylated chalcone present in hops (Humulus lupulus L.) and beer. Int J Cancer 117: 889-895, 2005.
4. Colgate EC, Miranda CL, Stevens JF, Bray TM and Ho E: Xanthohumol, a prenylflavonoid derived from hops induces apoptosis and inhibits NF-kappaB activation in prostate epithelial cells. Cancer Lett 246: 201-209, 2007.
5. Delmulle L, Bellahcene A, Dhooge W, Comhaire F, Roelens F, Huvaere K, Heyerick A, Castronovo V and De KD: Antiproliferative properties of prenylated flavonoids from hops (Humulus lupulus L.) in human prostate cancer cell lines. Phytomedicine 13: 732-734, 2006.
6. Goto K, Asai T, Hara S, Namatame I, Tomoda H, Ikemoto M and Oku N: Enhanced antitumor activity of xanthohumol, a diacylglycerol acyltransferase inhibitor, under hypoxia. Cancer Lett 219: 215-222, 2005.
7. Hussain K and El-Serag HB: Epidemiology, screening, diagnosis and treatment of hepatocellular carcinoma: Minerva Gastroenterol Dietol 55: 123-138, 2009.
8. El-Serag HB and Mason AC: Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 340: 745-750, 1999.
9. El-Serag HB, Marrero JA, Rudolph L and Reddy KR: Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology 134: 1752-1763, 2008.
10. Bruix J, Boix L, Sala M and Llovet JM: Focus on hepatocellular carcinoma. Cancer Cell 5: 215-219, 2004.
11. Farazi PA and DePinho RA: Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer 6: 674-687, 2006.
12. Hellerbrand C, Bumes E, Bataille F, Dietmaier W, Massoumi R and Bosserhoff AK: Reduced expression of CYLD in human colon and hepatocellular carcinomas. Carcinogenesis 28: 21-27, 2007.
13. Hellerbrand C, Amann T, Schlegel J, Wild P, Bataille F, Spruss T, Hartmann A and Bosserhoff AK: The novel gene MIA2 acts as a tumour suppressor in hepatocellular carcinoma. Gut 57: 243-251, 2008.
14. Weiss TS, Jahn B, Cetto M, Jauch KW and Thasler WE: Collagen sandwich culture affects intracellular polyamine levels of human hepatocytes. Cell Prolif 35: 257-267, 2002.
15. Muhlbauer M, Fleck M, Schutz C, Weiss T, Froh M, Blank C, Scholmerich J and Hellerbrand C: PD-L1 is induced in hepatocytes by viral infection and by interferon-alpha and -gamma and mediates T cell apoptosis. J Hepatol 45: 520-528, 2006.
16. Hellerbrand C, Muhlbauer M, Wallner S, Schuierer M, Behrmann I, Bataille F, Weiss T, Scholmerich J and Bosserhoff AK: Promoter-hypermethylation is causing functional relevant downregulation of methylthioadenosine phosphorylase (MTAP) expression in hepatocellular carcinoma. Carcinogenesis 27: 64-72, 2006.
17. Amann T, Bataille F, Spruss T, Muhlbauer M, Gabele E, Scholmerich J, Kiefer P, Bosserhoff AK and Hellerbrand C: Activated hepatic stellate cells promote tumorigenicity of hepatocellular carcinoma. Cancer Sci 100: 646-653, 2009.
18. Muhlbauer M, Allard B, Bosserhoff AK, Kiessling S, Herfarth H, Rogler G, Scholmerich J, Jobin C and Hellerbrand C: Differential effects of deoxycholic acid and taurodeoxycholic acid on NFkappa B signal transduction and IL-8 gene expression in colonic epithelial cells. Am J Physiol Gastrointest Liver Physiol 286: G1000-G1008, 2004.
19. Muhlbauer M, Bosserhoff AK, Hartmann A, Thasler WE, Weiss TS, Herfarth H, Lock G, Scholmerich J and Hellerbrand C: A novel MCP-1 gene polymorphism is associated with hepatic MCP-1 expression and severity of HCV-related liver disease. Gastroenterology 125: 1085-1093, 2003.
20. Arsura M and Cavin LG: Nuclear factor-kappaB and liver carcinogenesis. Cancer Lett 229: 157-169, 2005.
21. Pikarsky E, Porat RM, Stein I, Abramovitch R, Amit S, Kasem S, Gutkovich-Pyest E, Urieli-Shoval S, Galun E and Ben-Neriah Y: NF-kappaB functions as a tumour promoter in inflammationassociated cancer. Nature 431: 461-466, 2004.
22. Iguchi A, Kitajima I, Yamakuchi M, Ueno S, Aikou T, Kubo T, Matsushima K, Mukaida N and Maruyama I: PEA3 and AP-1 are required for constitutive IL-8 gene expression in hepatoma cells. Biochem Biophys Res Commun 279: 166-171, 2000.
23. Joshi-Barve S, Barve SS, Amancherla K, Gobejishvili L, Hill D, Cave M, Hote P and McClain CJ: Palmitic acid induces production of proinflammatory cytokine interleukin-8 from hepatocytes. Hepatology 46: 823-830, 2007.
24. Kubo F, Ueno S, Hiwatashi K, Sakoda M, Kawaida K, Nuruki K and Aikou T: Interleukin 8 in human hepatocellular carcinoma correlates with cancer cell invasion of vessels but not with tumor angiogenesis. Ann Surg Oncol 12: 800-807, 2005.
25. Ren Y, Poon RT, Tsui HT, Chen WH, Li Z, Lau C, Yu WC and Fan ST: Interleukin-8 serum levels in patients with hepatocellular carcinoma: correlations with clinicopathological features and prognosis. Clin Cancer Res 9: 5996-6001, 2003.
26. Lee SH, Kim HJ, Lee JS, Lee IS and Kang BY: Inhibition of topoisomerase I activity and efflux drug transporters' expression by xanthohumol from hops. Arch Pharm Res 30: 1435-1439, 2007.
27. Lust S, Vanhoecke B, Janssens A, Philippe J, Bracke M and Offner F: Xanthohumol kills B-chronic lymphocytic leukemia cells by an apoptotic mechanism. Mol Nutr Food Res 49: 844-850, 2005.
28. Monteiro R, Faria A, Azevedo I and Calhau C: Modulation of breast cancer cell survival by aromatase inhibiting hop (Humulus lupulus L.) flavonoids. J Steroid Biochem Mol Biol 105: 124-130, 2007.
29. Ho YC, Liu CH, Chen CN, Duan KJ and Lin MT: Inhibitory effects of xanthohumol from hops (Humulus lupulus L.) on human hepatocellular carcinoma cell lines. Phytother Res 22: 1465-1468, 2008.
30. Dell'Eva R, Ambrosini C, Vannini N, Piaggio G, Albini A and Ferrari N: AKT/NF-kappaB inhibitor xanthohumol targets cell growth and angiogenesis in hematologic malignancies. Cancer 110: 2007-2011, 2007.
31. Van HR, Ten Hagen TL and Eggermont AM: TNF-alpha in cancer treatment: molecular insights, antitumor effects, and clinical utility. Oncologist 11: 397-408, 2006.
32. Bertazza L and Mocellin S: Tumor necrosis factor (TNF) biology and cell death. Front Biosci 13: 2736-2743, 2008.
33. Falschlehner C, Emmerich CH, Gerlach B and Walczak H: TRAIL signalling: decisions between life and death. Int J Biochem Cell Biol 39: 1462-1475, 2007.
34. Shen HM and Tergaonkar V: NFkappaB signaling in carcinogenesis and as a potential molecular target for cancer therapy. Apoptosis 14: 348-363, 2009.
35. Zhang S, Li J, Jiang Y, Xu Y and Qin C: Programmed cell death 4 (PDCD4) suppresses metastastic potential of human hepatocellular carcinoma cells. J Exp Clin Cancer Res 28: 71, 2009.
36. Salvi A, Sabelli C, Moncini S, Venturin M, Arici B, Riva P, Portolani N, Giulini SM, De PG and Barlati S: MicroRNA-23b mediates urokinase and c-met downmodulation and a decreased migration of human hepatocellular carcinoma cells. FEBS J 276: 2966-2982, 2009.
37. Shirouzu Y, Ryschich E, Salnikova O, Kerkadze V, Schmidt J and Engelmann G: Rapamycin inhibits proliferation and migration of hepatoma cells in vitro. J Surg Res (In press).
38. Dong G, Chen Z, Li ZY, Yeh NT, Bancroft CC and Van WC: Hepatocyte growth factor/scatter factor-induced activation of MEK and PI3K signal pathways contributes to expression of proangiogenic cytokines interleukin-8 and vascular endothelial growth factor in head and neck squamous cell carcinoma. Cancer Res 61: 5911-5918, 2001.
39. Yang JY, Della-Fera MA, Rayalam S and Baile CA: Effect of xanthohumol and isoxanthohumol on 3T3-L1 cell apoptosis and adipogenesis. Apoptosis 12: 1953-1963, 2007.
40. Spencer JP: Metabolism of tea flavonoids in the gastrointestinal tract. J Nutr 133: S3255-S3261, 2003.
41. Nikolic D, Li Y, Chadwick LR, Pauli GF and van Breemen RB: Metabolism of xanthohumol and isoxanthohumol, prenylated flavonoids from hops (Humulus lupulus L.), by human liver microsomes. J Mass Spectrom 40: 289-299, 2005.
42. Yilmazer M, Stevens JF and Buhler DR: In vitro glucuronidation of xanthohumol, a flavonoid in hop and beer, by rat and human liver microsomes. FEBS Lett 491: 252-256, 2001.
43. Yilmazer M, Stevens JF, Deinzer ML and Buhler DR: In vitro biotransformation of xanthohumol, a flavonoid from hops (Humulus lupulus), by rat liver microsomes. Drug Metab Dispos 29: 223-231, 2001.
44. Scalbert A and Williamson G: Dietary intake and bioavailability of polyphenols. J Nutr 130: S2073-S2085, 2000.
45. Hussong R, Frank N, Knauft J, Ittrich C, Owen R, Becker H and Gerhauser C: A safety study of oral xanthohumol administration and its influence on fertility in Sprague Dawley rats. Mol Nutr Food Res 49: 861-867, 2005.
46. Vanhoecke BW, Delporte F, Van BE, Heyerick A, Depypere HT, Nuytinck M, De KD and Bracke ME: A safety study of oral tangeretin and xanthohumol administration to laboratory mice. In Vivo 19: 103-107, 2005.